Revance Therapeutics (RVNC) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

RVNC Revance Therapeutics

Watchlist

3.530
+0.580+19.66%

Close Aug 9 16:00 ET

3.600
+0.070+1.98%

Post 20:02 ET

370.03MMarket Cap-1096P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Sector Update: Health Care Stocks Rise in Friday Afternoon Trading
MT NewswiresAug 9 14:23 ET
Express News | Revance Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q2 EPS Results and Raised Its FY24 Net Product Revenue Guidance Above Estimates
BenzingaAug 9 13:03 ET
Revance Therapeutics Shares Jump After Q2 Loss Narrows, Revenue Rises
MT NewswiresAug 9 12:22 ET
Express News | Piper Sandler Maintains Overweight on Revance Therapeutics, Lowers Price Target to $6
BenzingaAug 9 10:05 ET
Revance Therapeutics Reports Surge in Aesthetic Portfolio Growth
TipRanksAug 9 09:28 ET
Revance Therapeutics Is Maintained at Buy by Stifel
Dow JonesAug 9 08:56 ET

Comments

102679617

May 10 10:45

$Revance Therapeutics (RVNC.US)$ nice bounce

Ezra Benner

Apr 26 09:20

Up and Up

$Revance Therapeutics (RVNC.US)$

Moomoo AI

Mar 1 06:54

Despite strong revenue growth, the significant share price drop indicates potential unresolved company challenges. It's advised to scrutinize the stock and forecasts before purchase.

Even After Rising 34% This Past Week, Revance Therapeutics (NASDAQ:RVNC) Shareholders Are Still Down 77% Over the Past Year

Kevin Travers

Jan 8 09:58

Columns Revance Therapeutics -14% on Preliminary Q4, FY24 Outlook

$Revance Therapeutics (RVNC.US)$ Monday showed sales volumn rose 22% in Q3, reflecting positive feedback on the product's performance profile and the new pricing strategy. The firm predicted an unaudited Q4 and full-year 2023 revenue between $58 million and $59 million and $212 million and $213 million, representing approximately 28% and 80% YoY growth, respectively.

Moomoo AI

Dec 25, 2023 06:26

Concerns raised by insiders' stock selling. CEO Mark Foley's sale was price-wise favorable. Despite no recent insider purchase, the 1.9% insider stake suggests alignment with shareholders.